Sign In
Free Newsletter
Novo Nordisk to evaluate semaglutide weight loss implant
Novo Nordisk will evaluate Vivani Medical's semaglutide implant for chronic weight management under a new development agreement.
Novo Nordisk Wegovy pill tops 3M prescriptions
Novo Nordisk says its oral Wegovy weight-loss pill surpassed 3 million U.S. prescriptions in five months after launch.
Novo Nordisk launches Wegovy subscription plan with savings
The new option offers lower monthly pricing for self-pay patients via telehealth platforms, such as Weight Watchers, LifeMD, Hims & Hers and Sesame, to expand access to GLP-1 weigh loss drugs.
Novo Nordisk, Hims & Hers settle GLP-1 drug dispute
The settlement between Novo Nordisk and Hims & Hers allows the telehealth platform to sell FDA-approved Wegovy and Ozempic GLP-1 drugs.
Hims & Hers pulls copycat Wegovy pill amid legal action
Hims & Hers stopped offering compounded GLP-1 semaglutide pills following a Novo Nordisk lawsuit and FDA concerns over copycat drugs.
Novo Nordisk threatens legal action over Hims Wegovy copy (updated)
Novo Nordisk is threatening the telehealth provider over a $49 compounded copycat therapy, escalating scrutiny of GLP-1 weight-loss drug alternatives.
Novo Nordisk’s Wegovy weight loss pill hits US market
The pharma launched a once-daily alternative to its injections, available nationwide after FDA approval at 70,000 pharmacies with starting doses priced at $149 per month.
FDA approves Wegovy weight loss pill from Novo Nordisk
The first oral GLP-1 obesity drug will launch in the U.S. at a $149 starting price in 2026.
Novo Nordisk, Eli Lilly cut GLP-1 drug costs under Medicare
The deals with the Trump administration will lower prices for weight loss and diabetes medications to make them more affordable for patients.
Novo Nordisk ends Hims & Hers deal over Wegovy knockoffs
The conclusion of the collaboration comes as the drug maker cites illegal sales of compounded knockoff weight loss drugs and expresses growing concerns over patient safety.
Novo Nordisk expands Wegovy access as FDA bans semaglutide copies
The Swiss drugmaker – which has its U.S. headquarters in Plainsboro – is launching a series of initiatives to offer patients authentic versions of its blockbuster weight-loss treatment.
Frier Levitt to host webinar on GLP-1 legal risks
The boutique health care firm will host a May 15 event exploring compounding, legal risks, FDA regulations and the growing role of payers in obesity treatment.
